| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US10751333 | AZURITY | Compositions and kits for omeprazole suspension |
Jul, 2039
(15 years from now) | |
| US11103492 | AZURITY | Compositions and kits for omeprazole suspension |
Jul, 2039
(15 years from now) | |
| US11633478 | AZURITY | Compositions and kits for Omeprazole suspension |
Jul, 2039
(15 years from now) | |
| US11771686 | AZURITY | Compositions and kits for omeprazole suspension |
Mar, 2040
(15 years from now) | |
Konvomep is owned by Azurity.
Konvomep contains Omeprazole; Sodium Bicarbonate.
Konvomep has a total of 4 drug patents out of which 0 drug patents have expired.
Konvomep was authorised for market use on 30 August, 2022.
Konvomep is available in for suspension;oral dosage forms.
Konvomep can be used as short term treatment of active benign gastric ulcer.
The generics of Konvomep are possible to be released after 01 March, 2040.
Drugs and Companies using OMEPRAZOLE; SODIUM BICARBONATE ingredient
Market Authorisation Date: 30 August, 2022
Treatment: Short term treatment of active benign gastric ulcer
Dosage: FOR SUSPENSION;ORAL
More Information on Dosage
KONVOMEP family patents
